...
首页> 外文期刊>Trials >Permissive underfeeding versus target enteral feeding in adult critically ill patients (PermiT Trial): a study protocol of a multicenter randomized controlled trial
【24h】

Permissive underfeeding versus target enteral feeding in adult critically ill patients (PermiT Trial): a study protocol of a multicenter randomized controlled trial

机译:成人危重患者的允许进食不足和目标肠内喂养(PermiT试验):一项多中心随机对照试验的研究方案

获取原文

摘要

Background Nutritional support is an essential part of the management of critically ill patients. However, optimal caloric intake has not been systematically evaluated. We aim to compare two strategies of enteral feeding: permissive underfeeding versus target feeding. Method/Design This is an international multi-center randomized controlled trial in critically ill medical- surgical adult patients. Using a centralized allocation, 862 patients will be randomized to permissive underfeeding or target feeding. Patients in the permissive group receive 50% (acceptable range is 40% to 60%) of the calculated caloric requirement, while those in the targeted group receive 100% (acceptable range 70% to 100%) of the calculated caloric requirement. The primary outcome is 90-day all-cause mortality. Secondary outcomes include ICU and hospital mortality, 28-day, and 180-day mortality as well as health care-associated infections, organ failure, and length of stay in the ICU and hospital. The trial has 80% power to detect an 8% absolute reduction in 90-day mortality assuming a baseline risk of death of 25% at an alpha level of 0.05. Discussion Patient recruitment started in November 2009 and is currently active in five centers. The Data Monitoring Committee advised continuation of the trial after the first interim analysis. The study is expected to finish by November 2013. Trial registration Current Controlled Trials ISRCTN68144998
机译:背景技术营养支持是危重病人管理的重要组成部分。但是,尚未系统评估最佳热量摄入。我们的目的是比较两种肠内喂养策略:允许性不足喂养与目标喂养。方法/设计这是一项针对重症医学手术成年患者的国际多中心随机对照试验。使用集中分配,将把862名患者随机分配到允许性的喂食不足或目标喂食中。允许组的患者接受计算的热量需求的50%(可接受范围为40%至60%),而目标组的患者接受计算的热量需求的100%(可接受范围为70%至100%)。主要结局是90天全因死亡率。次要结局包括ICU和医院的死亡率,28天和180天的死亡率以及与卫生保健相关的感染,器官衰竭以及在ICU和医院的住院时间。假设基线死亡风险为25%(α值为0.05),则该试验具有80%的能力检测90天死亡率绝对降低8%。讨论患者招募始于2009年11月,目前活跃于五个中心。数据监控委员会建议在进行第一次中期分析后继续进行试验。预计该研究将于2013年11月完成。试验注册当前对照试验ISRCTN68144998

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号